Markets are digesting one of the wildest earnings weeks in memory. Of the Magnificent Seven names that reported, results diverged sharply: Microsoft surged 8% on strong cloud growth and Amazon jumped 10% on AWS acceleration and a favorable Prime Day shift. Meta crashed 10% on a miss and softer guidance tied to elevated AI capital spending, while Apple fell 4% on cost concerns and a cautious outlook. Alphabet, already down 7.1% the prior week after raising capex, extended its slide to roughly 15% from its recent high. Micron, caught in the same AI-hardware anxiety, fell 41% from its high. The selloff forced Situational Awareness, a hedge fund founded by former OpenAI researcher Leopold Aschenbrenner, to unwind large AI-stock positions after heavy losses. That forced unwind appears to have marked a local bottom: momentum stocks staged one of their best days ever Thursday and extended gains Friday, even after logging one of their worst months on record in July.
Wednesday's FOMC meeting added its own drama: the Fed held rates at 3.50–3.75% by a 9-3 vote, with three dissenters (Hammack, Kashkari, Logan) pushing for a hike given oil still above $100/barrel. Warsh's next major test is the Jackson Hole symposium (Aug 27–29); the next FOMC meeting isn't until September 15–16, but CME FedWatch has already started pricing a slight majority chance of a September hike. Against that backdrop, this week is quieter on earnings (Palantir Monday, AMD and SpaceX Tuesday, Ahold Delhaize Wednesday), but Friday's July jobs report is the main event. June's shocking +57,000 print, barely half the +110,000 consensus, raises the stakes for whether the labor market is genuinely cooling or just had one soft month.
Growth expectations are exceptional even by this earnings season's standards. The question is less whether Palantir beats and more whether the print can justify one of the market's most stretched valuations.
Reports the day after Micron's 41% drawdown from its high, amid broader AI-hardware anxiety. A clean beat with a strong hyperscale order book would help separate AMD's story from memory-specific pricing fears.
The market's first real look under the hood since the IPO. Given how harshly this earnings season has punished capex-heavy space/tech stories, guidance commentary will matter as much as the headline numbers.
The AI Marketing Cloud enters the print after raising FY26 guidance last quarter. The run of consecutive beats is now a talking point in its own right. A miss would be a bigger story than the number.
GLP-1 franchise depth remains the core story. ADA 2026 data showed strong efficacy across the next-gen pipeline; watch competitive share commentary against the rest of the obesity/diabetes field.
Small-cap rare-disease name reporting the same evening as SanDisk and Novo Nordisk. Commercial ramp of its NPC treatment is the main line item to track.
Reports the same evening as Novo Nordisk and Zevra, and directly extends this cycle's memory/chip anxiety theme (Micron down 41% from its high). Goldman expects a strong quarter on continued NAND supply tightness despite the stock's pullback.
Oscar is the week's most-watched healthcare name for a reason: the stock has more than doubled off its lows and is trading near an all-time high, yet it now sits above the average analyst price target of $20–21. The market has already priced in a lot of good news. The bull case is straightforward: Q1's 70.5% medical loss ratio was a dramatic improvement, membership grew more than 50% year-over-year to 3.17 million, and net income swung to roughly $679M from $275M a year earlier. Management has paired this with tech-led cost discipline (SG&A ratio falling toward incumbent efficiency levels) and reaffirmed full-year guidance.
The bear case does not dispute Oscar's ability to grow. It centers on whether Q1's margin strength holds up. Full-year MLR guidance of 82.4–83.4% is far higher than Q1's 70.5%, reflecting normal seasonality in healthcare utilization, so the real test is whether Q2 and Q3 confirm the improving cost trend rather than reverting toward the guided range. Layered on top is ACA policy risk: enhanced marketplace premium subsidies are set to expire, and prediction markets are already pricing an ~87% chance they are not extended. The market is treating that as the base case rather than a surprise. Oscar's own risk-adjustment transfer payables ran near 24% of direct premium revenue in Q1, a figure that can swing results if the morbidity mix shifts. With the stock priced for continued execution, Thursday's print carries more weight than the modest $0.41 EPS estimate would suggest.
June's shock miss (+57K vs. +110K est.) followed downward revisions to April and May. A similarly soft July print hardens September rate-cut chatter; a rebound muddies the picture.
Three inflation hawks (Hammack, Kashkari, Logan) dissented in favor of a hike. With six weeks until the next meeting, incoming data carries outsized weight.
A hedge fund's forced liquidation after AI-stock losses coincided with what looks like a local bottom. Momentum stocks had one of their best days ever right after one of their worst months.
Microsoft and Amazon were rewarded for cloud strength; Meta, Apple, and Alphabet were punished on cost and guidance. Palantir and AMD test whether that split extends further down the AI complex.
No resolution yet to the Iran conflict. Energy prices remain the wildcard input to every inflation and Fed conversation this month.
The Aug 27–29 symposium is now the next major Fed communication point before the September 15–16 meeting. Six weeks of data stand between here and there.
| Ticker | Company | When | Notes |
|---|---|---|---|
| PLTR | Palantir Technologies | Mon | See spotlight. |
| AMD | Advanced Micro Devices | Tue AMC | See spotlight. |
| SPCX | SpaceX | This Week | First public earnings report. See spotlight. |
| ZETA | Zeta Global | Tue AMC | 19 consecutive quarters of beats and guidance increases. See spotlight. |
| ADRNY | Ahold Delhaize | Wed BMO | European grocery read. |
| NVO | Novo Nordisk | Wed BMO | GLP-1 franchise. See spotlight. |
| SNDK | SanDisk | Wed AMC | Memory/chip anxiety read. See spotlight. |
| ZVRA | Zevra Therapeutics | Wed AMC | Rare-disease commercial ramp. See spotlight. |
| OSCR | Oscar Health | Thu BMO | Week's most-watched healthcare print. See expanded spotlight. |